Latest News for LSB
LSB Industries is upgraded to buy after strong FY25 results, robust NOL carryforwards, and an optimistic 2026 outlook. LXU reported FY25 revenues up 22.3% YoY and EPS of $0.22, beating estimates, with EBITDA up 25% and further improvements targeted. Substantial NOLs ($243.9M federal, $342.7M state) are protected by a poison pill, enhancing future tax efficiency and takeover defense.
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB,” “we,” “us,” “our,” or the “Company”) today announced results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Results and Recent Highlights Net sales of $165.0 million compared to $134.9 million in the fourth quarter of 2024 Net income of $16.1 million compared to a net loss of $9.1 million in the fourth quarter…
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB”) (NYSE: LXU), today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025 on February, 25, 2026 after the close of the stock market. LSB's management will host a conference call on Thursday, February, 26, 2026 at 10:00 am ET / 9:00 am CT to discuss these results. Participating in the call will be…
BEIJING, Feb. 6, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has received a notice, dated February 4, 2026, from legal…
BEIJING, Jan. 20, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has called an extraordinary general meeting of shareholders…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for LSB.
Senate Trading
No Senate trades found for LSB.
U.S. House Trading
No House trades found for LSB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.